Holen Sie sich die Stockscreener-App
1.675
5.14%
-0.075
Schlusskurs vom Vortag:
$1.75
Offen:
$1.83
24-Stunden-Volumen:
94,170
Relative Volume:
0.41
Marktkapitalisierung:
$22.74M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.2504
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
+9.21%
1M Leistung:
+5.06%
6M Leistung:
-23.85%
1J Leistung:
-5.14%
1-Tages-Spanne:
$1.67
$1.83
1-Wochen-Bereich:
$1.45
$1.83
52-Wochen-Spanne:
$0.7707
$6.40
Longeveron Inc Stock (LGVN) Company Profile
Firmenname
Longeveron Inc
Sektor
Branche
Telefon
305-302-7158
Adresse
1951 NW 7TH AVENUE, MIAMI
Vergleichen Sie LGVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.675 | 22.74M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.65 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.63 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.82 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.67 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.19 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire
FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha
Longeveron Files $70 Million Mixed Shelf - MarketScreener
Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener
Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World
Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals
FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa
FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com
Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView
FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com
Laromestrocel shows promise in Alzheimer’s trial - Investing.com India
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times
Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks
Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq
Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan
Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World
Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World
Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World
FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World
Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN
Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times
How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan
Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks
Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World
Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks
Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada
Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan
LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Longeveron® Announces World Health Organization Approval of “laro - The National Law Review
LGVNRLongeveron Latest Stock News & Market Updates - StockTitan
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times
Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq
Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com
Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks
Longeveron® Announces World Health Organization Approval of - GlobeNewswire
Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com
Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan
Longeveron announces board member resignation - MSN
Finanzdaten der Longeveron Inc-Aktie (LGVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):